Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon-alpha-n3 - AIM ImmunoTech

Drug Profile

Interferon-alpha-n3 - AIM ImmunoTech

Alternative Names: Alferon LDO; Alferon LDO (Low Dose Oral); Alferon N; Alferon N Gel; Alferon N Injection; Alferon N LDO; alpha-n3-IF; Altemol; Interferon alfa-N3; Interferon alfa-n3 human leukocyte derived (Alferon N Injection); Interferon-α-n3; Leukocyte interferon; Naturaferon; Natural alpha interferon

Latest Information Update: 05 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Stem Cell Innovations
  • Developer AIM ImmunoTech; Fujimoto Pharmaceutical; Howard University; National Institute of Allergy and Infectious Diseases; Swiss Department of Defence, Civil Protection and Sport; United States Army Medical Research Institute of Infectious Diseases
  • Class Antivirals; Interferons
  • Mechanism of Action Immunostimulants; Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Middle East respiratory syndrome coronavirus
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Human papillomavirus infections
  • Registered Hepatitis C; Inflammation; Multiple sclerosis; Viral infections
  • Preclinical Zika virus infection
  • No development reported Ebola virus infections; HIV infections; Influenza A virus H7N9 subtype; Influenza A virus infections; Influenza virus infections; Middle East respiratory syndrome coronavirus; Venezuelan equine encephalomyelitis; West Nile virus infections
  • Discontinued Kaposi's sarcoma; Small cell lung cancer

Most Recent Events

  • 23 Aug 2019 Hemispherx Biopharma is now called AIM ImmunoTech
  • 08 Feb 2019 9259972: No updates
  • 28 Oct 2018 No recent reports of development identified for research development in Ebola-virus-infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top